NCT01382407View on ClinicalTrials.gov

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

April 1, 2017

Study Completion Date

April 1, 2017

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Cetuximab

Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.

Trial Locations (2)

31096

Oncology Institute, Rambam Health Care Campus, Haifa

Rambam Health Care Campus, Haifa

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Rambam Health Care Campus

OTHER

NCT01382407 - Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab | Biotech Hunter | Biotech Hunter